Adaptive Biotechnologies to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference
Adaptive Biotechnologies (Nasdaq: ADPT), a commercial stage biotech company focused on adaptive immune system applications, has announced its participation in the Morgan Stanley 23rd Annual Global Healthcare Conference in New York.
Management will engage in a fireside chat on September 10th at 1:05 PM ET. Investors can access both live and archived webcasts of the presentation through the company's website investor section at adaptivebiotech.com.
Adaptive Biotechnologies (Nasdaq: ADPT), azienda biotecnologica in fase commerciale specializzata nelle applicazioni del sistema immunitario adattivo, ha annunciato la sua partecipazione al Morgan Stanley 23rd Annual Global Healthcare Conference a New York.
La direzione parteciperà a una conversazione informale il 10 settembre alle 13:05 ET. Gli investitori possono seguire la trasmissione in diretta o rivedere le registrazioni nella sezione investor del sito aziendale all'indirizzo adaptivebiotech.com.
Adaptive Biotechnologies (Nasdaq: ADPT), una compañía biotecnológica en fase comercial centrada en aplicaciones del sistema inmunitario adaptativo, ha anunciado su participación en la Morgan Stanley 23rd Annual Global Healthcare Conference en Nueva York.
La dirección participará en una charla el 10 de septiembre a la 1:05 PM ET. Los inversores pueden acceder a la transmisión en vivo y a las grabaciones a través de la sección de inversores del sitio web de la compañía en adaptivebiotech.com.
Adaptive Biotechnologies (Nasdaq: ADPT), 적응 면역 시스템 응용에 주력하는 상업 단계의 바이오테크 기업이 뉴욕에서 열리는 Morgan Stanley 23rd Annual Global Healthcare Conference에 참가한다고 발표했습니다.
경영진은 9월 10일 오후 1시 05분(동부시간)에 파이어사이드 채팅에 참여합니다. 투자자들은 회사 웹사이트의 투자자 섹션(adaptivebiotech.com)에서 생중계 및 아카이브된 웹캐스트를 시청할 수 있습니다.
Adaptive Biotechnologies (Nasdaq: ADPT), une société de biotechnologie en phase commerciale spécialisée dans les applications du système immunitaire adaptatif, a annoncé sa participation à la Morgan Stanley 23rd Annual Global Healthcare Conference à New York.
La direction participera à une discussion informelle le 10 septembre à 13h05 ET. Les investisseurs peuvent accéder aux webdiffusions en direct et aux enregistrements via la section investisseurs du site web de la société à adaptivebiotech.com.
Adaptive Biotechnologies (Nasdaq: ADPT), ein Biotechnologieunternehmen in der kommerziellen Phase mit Schwerpunkt auf Anwendungen des adaptiven Immunsystems, hat seine Teilnahme an der Morgan Stanley 23rd Annual Global Healthcare Conference in New York angekündigt.
Das Management wird am 10. September um 13:05 Uhr ET an einem Gespräch im kleinen Kreis teilnehmen. Investoren können die Live-Übertragung sowie archivierte Webcasts der Präsentation über den Investor-Bereich der Unternehmenswebseite adaptivebiotech.com abrufen.
- None.
- None.
SEATTLE, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will be participating in the upcoming Morgan Stanley 23rd Annual Global Healthcare Conference in New York, NY.
Adaptive Biotechnologies’ management is scheduled to participate in a fireside chat on Wednesday, September 10th at 10:05 a.m. Pacific Time / 1:05 p.m. Eastern Time. Interested parties may access a live and archived webcast of the presentation on the “Investors” section of the company website at: www.adaptivebiotech.com.
About Adaptive Biotechnologies
Adaptive Biotechnologies (“we” or “our”) is a commercial-stage biotechnology company focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. We believe the adaptive immune system is nature’s most finely tuned diagnostic and therapeutic for most diseases, but the inability to decode it has prevented the medical community from fully leveraging its capabilities. Our proprietary immune medicine platform reveals and translates the massive genetics of the adaptive immune system with scale, precision and speed. We apply our platform to partner with biopharmaceutical companies, inform drug development, and develop clinical diagnostics across our two business segments: Minimal Residual Disease (MRD) and Immune Medicine. Our commercial products and clinical pipeline enable the diagnosis, monitoring, and treatment of diseases such as cancer and autoimmune disorders. Our goal is to develop and commercialize immune-driven clinical products tailored to each individual patient.
ADAPTIVE INVESTORS
Karina Calzadilla, Vice President, Investor Relations and FP&A
201-396-1687
investors@adaptivebiotech.com
ADAPTIVE MEDIA
Erica Jones, Associate Corporate Communications Director
206-279-2423
media@adaptivebiotech.com
FAQ
When is Adaptive Biotechnologies (ADPT) presenting at the Morgan Stanley Healthcare Conference 2025?
How can investors watch Adaptive Biotechnologies' Morgan Stanley conference presentation?
What type of presentation will Adaptive Biotechnologies (ADPT) give at the Morgan Stanley conference?
What is Adaptive Biotechnologies' main business focus?
